塞力醫療(603716.SH):打造國內基於嚴肅醫學的面向精神障礙疾病的AI數字診療和全病程管理系統
格隆匯6月24日丨塞力醫療(603716.SH)在投資者互動平臺表示,公司的“海思靈曦”腦科學與類腦研究數智平臺,是由公司子公司海思太科(武漢)醫療科技有限公司與浙江大學醫學院附屬第一醫院精神衛生中心聯合發起的國家級重點項目,依託國家科技部“2030腦科學與類腦研究”重大專項及衛健委重點專項支持,聚焦抑鬱症、雙相情感障礙、ADHD等精神疾病領域,打造國內基於嚴肅醫學的面向精神障礙疾病的AI數字診療和全病程管理系統。平臺深度融合華爲昇騰算力與DeepSeek大模型,整合超10年臨牀數據及權威醫學共識,構建“預防-幹預-康復”全鏈條閉環,覆蓋AI輔助診斷、AI數字療法、科研隊列三大核心場景。通過知識圖譜與領域大模型技術,實現個性化治療方案設計,精準匹配患者需求,顯著提升診療效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.